Hostname: page-component-848d4c4894-sjtt6 Total loading time: 0 Render date: 2024-06-17T02:03:53.948Z Has data issue: false hasContentIssue false
  • English
  • Français

Study of the efficacy and safety of various pharmacotherapy regimens for atypical depression in the framework of bipolar affective disorder, recurrent depressive disorder, psychogenic depression

Published online by Cambridge University Press:  01 September 2022

M. Verbitskaya ,
N. Tyuvina  and
Y. Tyulpin
M. Verbitskaya*
Affiliation:
Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University), Department Of Psychiatry And Narcology, Clinic Of Psychiatry And Narcology Named After S.s. Korsakov, Moscow, Russian Federation
N. Tyuvina
Affiliation:
Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University), Department Of Psychiatry And Narcology, Clinic Of Psychiatry And Narcology Named After S.s. Korsakov, Moscow, Russian Federation
Y. Tyulpin
Affiliation:
Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University), Department Of Psychiatry And Narcology, Clinic Of Psychiatry And Narcology Named After S.s. Korsakov, Moscow, Russian Federation
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

To improve the effectiveness of treatment for atypical depression, it is necessary to revise the accumulated experience, taking into account new knowledge and drugs.

Objectives

Comparative study of the efficacy and safety of therapy for atypical depression (AtD) in the structure of bipolar affective disorder (BAD), recurrent depressive disorder (RDR) and psychogenic depression (PD).

Methods

Clinical and clinical follow-up methods examined 77 patients with AtD, of which 35 - with bipolar disorder, 18 - with RDR and 24 - with PD. Patients in all three groups received monotherapy with an antidepressant or a mood stabilizer, or a combination of antidepressant and antipsychotic, antidepressant and mood stabilizer, mood stabilizer and antipsychotic, as well as a combination of antidepressant, antipsychotic and mood stabilizer.

Results

Agomelatine was the most frequently used (27.3%) and effective in reducing MADRS in all groups both in monotherapy and in combination with other drugs. Also in the PD group, escitalopram and vortioxetine were highly effective. Of the antipsychotics, when combined with antidepressants, sulpiride was found to be the most effective. When comparing the tolerance of antidepressants in all groups showed the best results (by the CGI scale), agomelatine and venlafaxine, in the BAR group is also vortioxetine.

Conclusions

The best strategy for effective and safe treatment of atypical depression is the use of modern antidepressant, which does not increase the symptoms of the atypical spectrum and, if necessary, can be supplemented with some antipsychotics.

Disclosure

No significant relationships.

Keywords

recurrent depressive disorderpsychogenic depressionBipolar Affective Disorderatypical depression
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S565 - S566
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.